This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cyclical Stocks Pop on Vaccine Progress: 5 Solid Buys
by Tirthankar Chakraborty
Positive news on the COVID-19 vaccine front revitalized the U.S. economy and vis-a-vis cyclical stocks like General Motors (GM), Delta Apparel (DLA) and Deere (DE).
5 Top-Performing ETFs of Last Week
by Sanghamitra Saha
Last week for Wall Street was all about vaccine optimism marred somewhat by rising virus cases and fears of further lockdowns.
Merck (MRK) to Buy OncoImmune, Add Late-Stage COVID-19 Treatment
by Zacks Equity Research
The acquisition of OncoImmune will boost Merck's (MRK) portfolio with CD24Fc, a candidate in phase III studies for the treatment of patients with severe and critical COVID-19.
Pfizer/BioNTech Seek Nod for Emergency Use of COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.
4 Sectors to Prosper in Thanksgiving Week
by Sanghamitra Saha
Back-to-back positive vaccine updates have offered sweet surprises to Wall Street from the start of the Thanksgiving month this year.
Markets Up on Sunny Holiday Outlook
by Mark Vickery
The NRF announced it expects U.S. holiday shopping season to grow 5.2% year over year, based on pent-up demand and higher U.S. savings rates during the pandemic.
AstraZeneca-Oxford Vaccine at 70% Efficacy
by Mark Vickery
One very positive piece of news from the AZN-Oxford study is that the doses may be refrigerated at normal cooler temperatures.
Gilead (GILD) Down on COVID-19 Drug Remdesivir Update
by Zacks Equity Research
Gilead's (GILD) remdesivir should not be used for hospitalized COVID-19 patients, as per the WHO's conditional recommendation.
Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19
by Zacks Equity Research
Lilly's (LLY) rheumatoid arthritis drug, Olumiant gets Emergency Use Authorization for treating hospitalized COVID-19 patients in combination with Gilead's Veklury.
Stock Market News for Nov 20, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Thursday on hopes of restarting of Congressional negotiations for a fresh tranche of fiscal stimulus.
Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine candidate proves to be 95% effective in final analysis. Sanofi (SNY), Lilly (LLY), Merck (MRK) & Glaxo (GSK) provide FDA updates.
EOG Resources (EOG) Up 32.8% MTD: What's Behind the Rally?
by Zacks Equity Research
Improving oil prices on positive coronavirus vaccine results aid EOG Resources (EOG).
5 Top Stocks to Buy Amid Potential Economic Recovery
by Zacks Equity Research
With the U.S. economy showing steady signs of a recovery and promising vaccine trials, it will be prudent to invest in fundamentally sound stocks like Crocs (CROX) and FedEx (FDX).
Small Caps at the Forefront of Market Rally: 5 ETF Winners
by Sweta Killa
While the rally has been broad-based across all the market caps, small-caps stocks, as indicated by the Russell 2000 Index, has been outperforming and is hitting new all-time highs.
VBI Vaccines' (VBIV) Early Data on HBV Candidate Positive
by Zacks Equity Research
VBI Vaccines' (VBIV) early-stage hepatitis B virus immunotherapeutic candidate, VBI-2601, achieves promising immune response in patients on interim analysis.
Pfizer/BioNTech COVID-19 Vaccine Shows Final Efficacy of 95%
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 95% effective in final analysis.
Major Indices Fall Despite Positive Coronavirus Vaccine Data
by Indrajit Bandyopadhyay
Stock market declines as Pfizer (PFE) /BioNtech's (BNTX) vaccine candidate, with efficacy rate of 95%, gets overshadowed by fresh coronavirus cases and no sign of new fiscal stimulus.
Stock Market News for Nov 19, 2020
by Zacks Equity Research
Wall Street closed sharply lower on Wednesday on renewed threat of the latest surge in coronavirus infections.
What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?
by Ritujay Ghosh
Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.
U.S. Crude Hits its Highest Price in 2 Months: Here's Why
by Nilanjan Choudhury
Some of the top gainers of the S&P 500 during the past month include energy-related names like Devon Energy (DVN), Baker Hughes Company (BKR), Diamondback Energy (FANG) and Marathon Oil (MRO).
Bet on Quality ETFs as Vaccine Hope & Coronavirus Cases Rise
by Sweta Killa
Quality ETFs could enjoy smooth trading and generate market-beating returns in the current market environment.
Why Cyclical Sector ETFs Are Roaring to All-Time Highs
by Sweta Killa
Vaccine optimism has spurred buying in cyclical sectors, which are tied to economic activities.
The Zacks Analyst Blog Highlights: Pfizer, Goldman Sachs, Mattel, Glu Mobile and Nautilus
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Goldman Sachs, Mattel, Glu Mobile and Nautilus
Moderna (MRNA) COVID-19 Vaccine MAA Under Rolling Review in EU
by Zacks Equity Research
Moderna (MRNA) announces start of rolling review of its regulatory application, seeking marketing authorization for its coronavirus vaccine candidate.
Glaxo (GSK) Candidate Gets Breakthrough Tag for HIV Prevention
by Zacks Equity Research
FDA grants breakthrough designation to Glaxo's (GSK) long-acting injectable cabotegravir to decrease the risk of HIV acquisition in at-risk populations.